Enzalutamide

Tags: Drug.

Enzalutamide (marketed as Xtandi and formerly known as MDV3100) is an androgen receptor antagonist drug developed by the pharmaceutical company Medivation for the treatment of metastatic castration-resistant prostate cancer. Medivation has reported up to an 89% decrease in prostate specific antigen serum levels after a month of taking the medicine. Early preclinical studies also suggest that enzalutamide inhibits breast cancer cell growth. In August 2012 the U.S.

thumbnail

ATC prefix

None

CAS number

915087-33-1

ChEBI

68534

FDA UNII code

93T0T9GKNU

IUPAC name

4-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-55-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide

PubChem

15951529